Edition:
United States

People: MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

8.71USD
1:22pm EDT
Change (% chg)

$-0.22 (-2.46%)
Prev Close
$8.93
Open
$8.90
Day's High
$8.95
Day's Low
$8.68
Volume
11,353
Avg. Vol
56,572
52-wk High
$14.50
52-wk Low
$4.40

Iwaki, Yuichi 

Dr. Yuichi Iwaki, M.D., Ph.D., is President, Chief Executive Officer and Director of MediciNova, Inc. He is the company founder and served as the Chairman of the Board of Directors from our inception in September 2000 to March 2007, becoming Executive Chairman in July 2005, Acting Chief Executive Officer as of September 2005 and President and Chief Executive Officer as of March 2006. From September 2001 until January 2007, Dr. Iwaki also served as our consultant in connection with financing transactions and business development activities. Dr. Iwaki was a member of the Board of Avigen, Inc. from 1994 to 2008. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Dr. Iwaki is also a visiting professor at the Nihon University School of Medicine and Kyushu University. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 book chapters. Dr. Iwaki has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 25 years and serves on the board of directors of several biotechnology companies. Based on his medical background, relationships with leading Japanese biotechnology companies and extensive experiences as a professor and as an advisor to pharmaceutical companies,

Basic Compensation

Total Annual Compensation, USD 757,137
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 11,961
Fiscal Year Total, USD 769,098

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --